Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)
June 17, 2021 11:21 AM EDTUpdated 11:48 AM
Coronavirus

'No rea­son to slow down any­thing here': Cure­Vac plans to march on with Covid-19 vac­cine af­ter piv­otal fail­ure

Nicole DeFeudis

Editor

The day af­ter Cure­Vac re­vealed its mR­NA vac­cine failed a piv­otal tri­al, crush­ing the com­pa­ny’s stock, a group of an­a­lysts tuned in­to the com­pa­ny call …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times